FCGR2B and neoplasm: In relation to hepatic diseases, the expression levels of LSEC markers, including FcγRIIb, of HCC patients were sequentially lost during tumor progression [22], and it disappeared in 63% of cases in the peritumoral tissue samples of a tissue microarray of HCC [7].